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Abstract
Asymptomatic infection due to Strongyloides stercoralis
may result in severe disease after treatment with systemic
steroids. A case of S. stercoralis hyperinfection in a woman
who was treated with systemic steroids for cerebral tubercu-
losis is reported. A 52-year-old female patient was admit-
ted for a brain space–occupying lesion. A biopsy revealed
tuberculoid-like giant cells necrotizing granulomatous reac-
tion. Antituberculous (anti-tb) therapy and corticosteroids
were started for suspected cerebral tuberculosis. Ten days
after admission, the patient developed respiratory failure. A
chest computed tomography showed multiple dense periph-
eral nodular infiltrates not seen at admission chest x-ray. Tak-
ing the patient’s epidemiological background into account,
ivermectin treatment was initiated, leading to clear improve-
ment in her clinical condition. S. stercoralis was isolated from
a fecal sample. Ivermectin empirical treatment before initia-
tion of high-dose corticosteroids in patients from endemic ar-
eas could be the best strategy for prevention of hyperinfection
by this parasite.
Introduction
Strongyloidiasis is a parasitosis widely distributed in
tropical and subtropical regions of the world. The in-
fection prevalence is variable in Argentina, with a het-
erogeneous distribution; the northeast and northwest
are the two main endemic areas, with over 30 percent
of the population infected.[1, 2]
In immunosuppressed individuals, strongyloidiasis
can have potentially fatal complications, such as hy-
perinfection syndrome and disseminated strongyloidi-
asis.[3]
This article presents a S. stercoralis hyperinfection case
to highlight the importance of suspecting and prevent-
ing the presence of this infection in patients who are
due to receive immunosuppressive drugs, such as cor-
ticosteroids.
Case Description
A 52-year-old healthy female from Santiago del Es-
tero was admitted to the hospital with aphasia, dis-
orientation, and fever lasting for one month. She had
been previously evaluated in another institution for
several brain space–occupying lesions. A biopsy re-
vealed tuberculoid-like giant cells necrotizing granu-
lomatous reaction with multinucleated Langhans-type
cells. She was lost to follow-up, resulting in no treat-
ment initiation.
At present admission, the vital signs were tempera-
ture 37.8 °C, arterial blood pressure 100/60 mmHg,
and heart rate 82 beats/minute. Physical examina-
tion revealed disorientation, ataxia, and mutism, but
there was no other abnormal finding. Our labora-
tory results reported no anemia, white blood cell eleva-
tion, or platelet count abnormality. A differential with
eosinophil count was not performed. No renal or hep-
atic function abnormalities were found. C-reactive pro-
tein (CRP) was 14 (normal range: 0–5 mg/L). A brain
computed tomography (CT) showed multiple supra-
and infratentorial isodense lesions, with mild peri-
injury edema and post-surgical changes at the biopsy
site. A cerebrospinal fluid exam showed normal glu-
cose and proteins. The acid fast stain was negative.
Antituberculous (anti-tb) therapy and systemic corti-
costeroids were started for suspected cerebral tubercu-
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losis.
After ten days of treatment and slow improvement
of neurological symptoms, the patient developed di-
arrhea, persistent fever of 39 °C and hypoxemia. A
chest CT showed multiple dense peripheral nodular in-
filtrates in the upper lobes, middle lobe, and lingula, as
well as laminar bilateral pleural effusions. Piperacillin-
tazobactam was started for hospital-acquired infection.
Furthermore, oral metronidazole and vancomycin for
Clostridium difficile (toxin A and B positive in stool sam-
ple) were started while anti-tb treatment was contin-
ued. Given the patient’s worsening respiratory status
(PaO2/FiO2 142) and the persistence of diarrhea, a new
chest CT was obtained, which showed progression of
lung nodules and involvement of inferior lobes with
predominance of apical and posterior segments (Figure
1).
Taking the epidemiological background into consider-
ation, as well as the clinical and radiological findings,
a S. stercoralis hyperinfection was suspected. Empiri-
cal treatment with ivermectin was started. Smears of
peripheral blood showed 38 percent eosinophils. Im-
munoglobulin E was 2,348 Ul/ml. The stool specimen
parasitological examination revealed the presence of
the nematode S. stercoralis.After starting treatment with
ivermectin, the patient´s clinical condition improved,
and the need for oxygen decreased. A bronchoscopy
was performed, and the bronchoalveolar lavage cul-
ture was positive for M. tuberculosis. A new CT showed
resolution of the infiltrates (Figure 2), and the patient
was discharged 30 days after admission with outpa-
tient follow-up recommended.
Discussion
S. stercoralis can evolve over decades as a chronic para-
sitization in humans. Its cycle begins when the filar-
iform larvae of the soil penetrate the skin and reach
the pulmonary alveoli through the bloodstream; from
there, they ascend through the tracheobronchial tree,
are swallowed, and reach the duodenum and jejunum,
where they mature to adult female worms. These then
lay eggs by parthenogenesis and give rise to rhabditi-
form larvae that are not infectious for humans. Some
of these larvae can transform into filariform larvae in
the intestine itself and auto-infect the host through the
colorectal mucous membrane.[4–5] Hyperinfection by
S. stercoralis can produce a severe clinical picture with
high mortality (30–60%). The manifestations of pul-
monary strongyloidiasis occur as a result of two dif-
ferent situations: larval migration and hyperinfection.
Larval lung migration is part of the parasite’s ordinary
cycle and is generally asymptomatic. In a minority of
cases, larval migration triggers a marked hypersensi-
tivity reaction that causes cough, dyspnea, chest pain,
and fever with pulmonary infiltrates associated with
peripheral eosinophilia called Löffler’s syndrome. Per-
foration of the pulmonary alveoli causes small vessel
bleeding, exudation, and local inflammation. Many
parasites reach the adult state when they stay in the
lung for an extended period. Hyperinfection is charac-
terized by excessive worm burden. The massive larval
invasion of the lung generates cough and hemoptysis
by the migration of the larvae from the capillary bed to
the alveoli and can even lead to diffuse alveolar hem-
orrhage. A patient will present with cough, fever and
dyspnea and may be in a potentially catastrophic con-
dition. The absence of eosinophilia may indicate a sig-
nificant alteration of the immune response and a worse
prognosis.[2–6] Chest images may show diffuse inter-
stitial infiltrates, consolidation, or abscesses. When
the infection involves other organs besides the intes-
tine and lung, such as the heart, liver, lymph nodes,
central nervous system, stomach, or skin, it is con-
sidered a disseminated form. There is a known asso-
ciation between S. stercoralis hyperinfection and sec-
ondary bacterial infections, usually related to Gram-
negative rod bacteremia from injured intestinal mucous
membranes.[7, 8]
Corticosteroid use and HTLV-1 infection are the fac-
tors most associated with hyperinfection syndrome.[9]
Other predisposing conditions include neoplastic dis-
ease, chronic lung disease, autoimmune diseases,
transplantation, malnutrition, and immunosuppres-
sive treatments. Corticosteroid therapy is associated
with two to three times the risk of triggering a chronic
asymptomatic infection with S. stercoralis to a severe
form of the disease. In addition, symptoms associated
with hyperinfection may relapse because of corticos-
teroid use (for cerebral tuberculosis in this case) and the
delay of effective therapy for strongyloidiasis.[10] One
of the explanations for corticosteroids inducing hyper-
infection is acute suppression of eosinophilia and acti-
vation of lymphocytes. It has also been suggested that
corticosteroids could directly affect parasites by accel-
erating their transformation from filariform to rhabdi-
tiform larvae.[8]
In cases of hyperinfection and dissemination, the diag-
nosis is made by the direct examination of biological
samples: fecal matter, sputum, bronchial washing or
bronchoalveolar lavage.[6] Ivermectin is the treatment
of choice given that compared to albendazole and thi-
abendazole, ivermectin has a better safety profile.[11–
12]
In our case, the infection of brain tuberculosis demand-
ing corticosteroid therapy resulted in S. stercoralis hy-
perinfection. Although some authors argue that the ini-
tial T cell response to M. tuberculosis infection may play
a role in S. stercoralis hyperinfection, we believe that in
our patient, treatment with steroids was the main cause
based on the temporal correlation between its initiation
and the manifestations of the disease.
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Figure 1. A chest computed tomography (CT), showing multiple dense peripheral nodular infiltrates in the upper andm iddle lobes and the lingula
ten days after admission.
Figure 2. A chest computed tomography (CT) showing resolution of peripheral nodular infiltrates 26 days after admission.
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Conclusion
S. stercoralis hyperinfection should be suspected in pa-
tients with acute pulmonary symptoms who receive
immunosuppressive treatment and/or suffer from an
immunodeficiency illness in an endemic area of this
parasite.
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